Cancer Family
Oral Neoplasm
CI-CAN-00000301Explore in graph →
Non-malignant163 active trials2 evidence items
- NCIt
- C8989
Loading cancer entity…
Cancer Family
CI-CAN-00000301Explore in graph →
Clinical trials
604 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05604105 | Oral Cancer Awareness in Egypt | not yet recruiting | — | 1,844 | Ayat Gamal-AbdelNaserOTHER | 0 | Sep 29, 2026 | clinicaltrials |
| NCT06589804 | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | recruiting | Phase 3 | 158 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07195734 | Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer | recruiting | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07844551 | ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC | not yet recruiting | Phase 2 | 40 | Huashan HospitalOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT05136196 | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | recruiting | Phase 2 | 150 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06980038 | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer | recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07124000 | DESTINY-PANTUMOUR04(DP-04) | recruiting | — | 100 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07842211 | Feasibility and Validation of an Automated AI-Enabled Deep Ultraviolet (DUV) Cytology Platform for Point-of-Care Oral Cancer Triage(DEEP UV-M) | not yet recruiting | N/A | 270 | Anh LeOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07836829 | Risk Factors of Jaw Osteoradionecrosis in Oral Cavity Cancer Patients Post-Radiotherapy(AOITC) | not yet recruiting | — | 1,000 | AO Innovation Translation CenterOTHER | 0 | Sep 23, 2026 | clinicaltrials |
| NCT04671667 | Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 188 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05172245 | Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | recruiting | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT07060261 | Pre-Op MRI on Margin Status for Transoral Robotic Surgery for HPV+ Tonsillar Squamous Cell Carcinoma | recruiting | N/A | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05172258 | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | active not recruiting | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06258811 | Neoadjuvant Immunochemotherapy for LAOSCC | recruiting | Phase 3 | 134 | Lai-ping ZhongOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06623266 | Neck Observation or Elective Neck Dissection in cT1N0M0 OSCC | recruiting | N/A | 300 | Huashan HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06736379 | Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer | recruiting | Phase 1 | 41 | VLP TherapeuticsINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07827872 | Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 300 | caohaotianOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07343596 | Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery | recruiting | N/A | 20 | University of Wisconsin, MadisonOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT00542373 | Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer | active not recruiting | N/A | 338 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02734537 | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | recruiting | Phase 2 | 189 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05721755 | Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck | active not recruiting | Phase 3 | 290 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06055868 | People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity | active not recruiting | — | 133 | University of California, San FranciscoOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07812467 | Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 220 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05429099 | Mandibular Reconstruction Preplanning (ViPMR)(ViPMR) | recruiting | N/A | 420 | University of British ColumbiaOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07090070 | Evaluating Treatment Strategies for p53 Mutant Oral Cancer and Oral Cancer Precursors(p53 RCT) | recruiting | N/A | 636 | University of British ColumbiaOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07156227 | Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06761937 | Thermotherapy for Locally Advanced Head and Neck Cancer(TANCA-I) | active not recruiting | Phase 1 | 2 | Erasmus Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07690618 | Thermotherapy for Head and Neck Cancer Patients(TANCAP-I) | recruiting | Phase 1 | 30 | Erasmus Medical CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07484139 | H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)(NEO COMBAT XL) | not yet recruiting | Phase 2 | 26 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07794813 | Trop2-targeting NIR-II Molecular Probe for Precision Diagnosis of Oral Cancer | recruiting | — | 40 | Yunnan Cancer HospitalOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT00588770 | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 3 | 403 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT00867464 | Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls | active not recruiting | — | 8,670 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | not yet recruiting | Early Phase 1 | 40 | Lumina Pharmaceuticals IncINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03829033 | Photon Therapy Versus Proton Therapy in Early Tonsil Cancer.(ARTSCAN V) | recruiting | N/A | 100 | Lund University HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07058805 | Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer(COMPORT) | recruiting | Phase 2 | 50 | Olgun ElicinOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07784855 | Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer | not yet recruiting | N/A | 180 | West Virginia UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04576091 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer | active not recruiting | Phase 1 | 7 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07778368 | A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 20 | Shanghai East HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04333537 | Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | recruiting | Phase 2 / Phase 3 | 686 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06532279 | Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | recruiting | Phase 2 | 98 | NRG OncologyOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07441681 | Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin | recruiting | Phase 3 | 454 | NRG OncologyOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07766889 | Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06627270 | Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer | recruiting | Phase 2 | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07110142 | Tongue Proactive Strengthening Exercise Program Following Partial/Hemi Glossectomy and Reconstruction(T-PROSE) | recruiting | N/A | 40 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03085147 | A Dye for the Detection of Cancer of the Tongue and Mouth | active not recruiting | Phase 1 / Phase 2 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | active not recruiting | Phase 2 | 101 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT07717307 | Study Comparing Limited and Extensive Neck Surgery in Oral Cancer Patients With Neck Spread(ExtentN1) | recruiting | N/A | 80 | Kolhapur Cancer Centre - Cancer Centers of AmericaOTHER | 1 | Aug 4, 2026 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 29, 2026source: clinicaltrials